[Clinical observation on treatment of 75 mid-late stage cancer patients with yanshu Injection].
OBJECTIVE
To study the effect of Yanshu Injection (YI) used in comprehensive treatment on mid-late stage cancer.


METHODS
One hundred and fifty patients with malignant cancer were equally randomized into the comprehensive treatment group (group A) and the control group (group B), both groups were treated systematically according to the NCCN 2005 cancer practice guideline, but 20 ml of YI was given additionally to group A every day.


RESULTS
After treatment, the level of plasma CD4 and CD4/CD8 ratio were significantly lower in group B than those in group A (P < 0.05); the response rate (RR) was 32.00% (24/75) and 38.67% (29/75) in group B and A respectively, showing insignificant difference (P>0.05), and the clinical benefit rate (CBR)was 58.67% (44/75) in group A, lower than that in group B (85.33% (64/75), P< 0.05); the quality of life (QOL) in group A was superior to that in group B (P<0.05); and the incidence of main adverse reaction to chemotherapeutic agents was significantly lower in group A as compared to that in group B (P<0.05).


CONCLUSIONS
YI could regulate the function of T-lymphocyte subsets, raise the CBR and QOL and reduce adverse reaction of chemotherapy in patients with mid-late stage cancer.
Wang
Zhao-yang
ZY
The Fourth Affiliated Hospital of Guangxi Medical College, Guangxi 545005. wzy2349@sohu.com
Li
Gui-sheng
GS
Huang
Hai-xin
HX
D000328:Adult; D000470:Alkaloids / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D003131:Combined Modality Therapy; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007267:Injections; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D008517:Phytotherapy; D011807:Quinolizines / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000187:drug effects*; D000093842:Matrines
D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D004365:Drugs, Chinese Herbal; D011807:Quinolizines; D000093842:Matrines